Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)

Market Cap	7.69B
Revenue (ttm)	801.01M
Net Income (ttm)	213.51M
Shares Out	828.30M
EPS (ttm)	0.25
PE Ratio	36.47
Forward PE	n/a
Dividend	0.10 (1.07%)
Ex-Dividend Date	Jul 17, 2025

Volume	12,769,569
Average Volume	10,254,160
Open	9.25
Previous Close	9.28
Day's Range	9.22 - 9.42
52-Week Range	6.52 - 11.48
Beta	-0.22
RSI	60.43
Earnings Date	Aug 29, 2025

About SHA:603229

Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it offers development and manufacturing services to the pharmaceutical, cosmetics, and nutritional industries. The company was founded in 2010 and is b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 1,219
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603229

Financial Performance

In 2024, SHA:603229's revenue was 795.29 million, a decrease of -2.63% compared to the previous year's 816.77 million. Earnings were 206.79 million, a decrease of -18.55%.